Full-Time
Confirmed live in the last 24 hours
Produces synthetic DNA for biotechnology applications
$110k - $130kAnnually
Mid, Senior
Remote in USA
Candidates must be based in NY, NJ, or PA.
You match the following Twist Bioscience's candidate preferences
Employers are more likely to interview you if you match these preferences:
Twist Bioscience creates synthetic DNA for use in biotechnology, pharmaceuticals, and research. Their proprietary platform allows for the quick and accurate production of DNA sequences, providing instant feedback to customers. They stand out by offering high-quality DNA products at competitive prices, serving a wide range of clients including academic institutions and pharmaceutical companies. The company's goal is to support advancements in personalized medicine and genetic research through their innovative DNA synthesis solutions.
Company Size
1,001-5,000
Company Stage
IPO
Total Funding
$236.5M
Headquarters
South San Francisco, California
Founded
2013
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Disability Insurance
Life Insurance
401(k) Retirement Plan
Twist Bioscience named a Best Idea for 2025 at TD Cowen.
Absci, a pioneer in generative AI-driven drug discovery, and Twist Bioscience, a leader in high-quality synthetic DNA production through its silicon platform, have announced an innovative collaboration to create a novel therapeutic antibody using generative AI.
In other recent news, Twist Bioscience has secured a $15 million capital boost from a new financial agreement with XOMA Royalty Corporation.
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced it has entered into a royalty purchase agreement with XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator.
SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Mike Fero, Ph.D., as chief information officer.